Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Inhibiting androgen signaling using androgen signaling inhibitors (ASI) remains the primary treatment for castrate-resistant prostate cancer. Acquired resistance to androgen receptor (AR)-targeted therapy represents a major impediment to durable clinical response. Understanding resistance mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Maxwell, Pamela J., McKechnie, Melanie, Armstrong, Christopher W., Manley, Judith M., Ong, Chee Wee, Worthington, Jenny, Mills, Ian G., Longley, Daniel B., Quigley, James P., Zoubeidi, Amina, de Bono, Johann S., Deryugina, Elena, LaBonte, Melissa J., Waugh, David J.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Cancer Genes and Networks
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381111/
https://www.ncbi.nlm.nih.gov/pubmed/35302608
http://dx.doi.org/10.1158/1541-7786.MCR-21-0780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381111/
https://www.ncbi.nlm.nih.gov/pubmed/35302608
http://dx.doi.org/10.1158/1541-7786.MCR-21-0780

Ejemplares similares